Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology
Clinical Trials: Acute Myelogenous Leukemia (AML)
A listing of clinical trials currently looking for volunteers to enroll in Acute Myelogenous Leukemia (AML) studies. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Scottsdale : Call for Information (Investigational Site 0004)
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649 AM3)
California
Duarte : City of Hope
A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects with Acute Myeloid Leukemia Who Have Been Treated with an Allogeneic Hematopoietic Stem Cell Transplant
Duarte : City of Hope
A Phase I Study of 5-Fluoro-2-deoxycytidine with Tetrahydrouridine (FdCyd + THU) in Myeloid Leukemia and MDS
Duarte : City of Hope
A Randomized, Prospective, Double Blind, Placebo-Controlled, Phase 3 Study of US-ATG-F Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome Patients after Allogeneic Stem Cell Transplantation from Unrelated Donors
Duarte : City of Hope
FLT3 Mutation Diagnostic Assay Development Study
Duarte : City of Hope
Multi-Center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan X 4 (CloBu4) Regimen
Florida
Tampa : Call for Information (Investigational Site 0006)
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649 AM3)
Georgia
Savannah : Memorial University Medical Center
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD
Illinois
Chicago : Univerity of Chicago
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Maryland
Baltimore : Call for Information (Investigational Site 0001)
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649 AM3)
Michigan
Ann Arbor : University of Michigan Health System
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Missouri
St. Louis : Washington University at St. Louis Siteman Cancer Center
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
New York
New York : Memorial Sloan Kettering Cancer Center
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Pennsylvania
Philadelphia : Hospital of the University of Pennsylvania
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Philadelphia : Temple University at Jeanes Hospital
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Texas
Houston : Call for Information (Investigational Site 0002)
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649 AM3)
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
BMTCTN0901: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Morgantown : West Virginia University - Clinical Trials Research Unit
VOS-AML-301: A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
Canada
Kirkland : Merck Frosst Canada Ltd.
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649 AM3)
